Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
VERSATILE-002 Trial for First Line Treatment of Recurrent/Metastatic Head and Neck Cancer with Combination PDS0101-KEYTRUDA® is Now Open and Recruiting Patients VERSATILE-002 Trial for First Line Tre
FLORHAM PARK, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc
PDS Biotech progresses second Phase 2 human clinical trial of PDS0101 PDS Biotech progresses second Phase 2 human clinical trial of PDS0101
FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cance
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2020 Results - Earnings Call Transcript
01:07pm, Thursday, 13'th Aug 2020
PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2020 Earnings Conference Call August 13, 2020 08:00 ET Company Participants Deanne Randolph - Investor Relations Frank Bedu-Addo - Chief Executive Office
PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update
10:00am, Thursday, 13'th Aug 2020
FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc
PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock
01:05pm, Tuesday, 11'th Aug 2020
FLORHAM PARK, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel can
PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock
08:05pm, Monday, 10'th Aug 2020
FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel can
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
3 “Strong Buy” Healthcare Stocks Under $5 That Could See Outsized Gains
09:19pm, Thursday, 06'th Aug 2020
The stock market just keeps going up, up and away. COVID-19 continues to have a choke hold on the economy, yet stocks have pulled off an incredible recovery, with the S&P 500 up 50% since its March lo
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
08:05pm, Thursday, 30'th Jul 2020
FLORHAM PARK, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc
PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19
12:30pm, Monday, 27'th Jul 2020
Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccinationFLORHAM PARK, N.J., July 2
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the Phase III Archway study evaluating its i
Sustenance vs Succour: With political will, PDS can be reformed
06:45am, Monday, 20'th Jul 2020
Weekly DBT through biometric-enabled electronic debit cards can be considered
PDS Biotechnology (NASDAQ:PDSB) Upgraded to Hold at Zacks Investment Research
06:00am, Sunday, 19'th Jul 2020
Zacks Investment Research upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zac
